Accurate, modern TB diagnosis and complete treatment support β from CBNAAT/GeneXpert testing to the government's free DOTS programme and specialist input for drug-resistant TB. Led by Dr. Rahul Katyal, MD Pulmonary Medicine & Director of Critical Care.
π Sector 69, SAS Nagar (Mohali), Punjab Β· Serving Chandigarh Tri-City
India carries one of the highest tuberculosis burdens in the world, and TB remains a major public-health priority. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and most often affects the lungs (pulmonary TB), but it can involve almost any part of the body. It spreads through the air when a person with active lung TB coughs or sneezes.
The good news is that TB is curable. With accurate diagnosis and a full, correctly-taken course of medicines, the great majority of patients recover completely. The two biggest challenges are diagnosing TB early and making sure treatment is completed β stopping early is the main reason TB becomes drug-resistant.
The most common form, affecting the lungs. It is the type that can spread to others and typically presents with a long-standing cough, fever and weight loss.
TB outside the lungs β affecting lymph nodes, the pleura (causing a pleural effusion), spine, abdomen, brain and other organs. It is usually not infectious to others.
TB that does not respond to the main first-line drugs (isoniazid and rifampicin). It needs longer, individualised regimens under specialist supervision, coordinated with the government programme.
Modern TB diagnosis is faster and more accurate than ever, thanks to molecular testing.
Examining sputum for TB bacteria (AFB smear) is a long-established, widely available test, useful for diagnosis and for monitoring treatment response.
A rapid molecular test that detects TB DNA within hours and also identifies rifampicin resistance β a key marker of MDR-TB. It is now the preferred first test in most cases.
Interferon-gamma release assays help identify latent (dormant) TB infection, particularly useful for contacts and before starting immune-suppressing treatments.
A chest X-ray shows the extent of lung disease. For extrapulmonary TB, samples such as pleural fluid or lymph-node tissue are collected and tested to confirm the diagnosis.
India follows the DOTS strategy (Directly Observed Treatment, Short-course) under the National TB Elimination Programme. Drug-sensitive TB is treated for about six months with a fixed combination of anti-TB drugs, split into an intensive phase and a continuation phase. Diagnostic tests and medicines are provided free of cost at public facilities, and patients are notified and supported through the government NIKSHAY system.
Completing the full course is essential. Many people feel better within a few weeks and are tempted to stop β but stopping early lets the bacteria survive and become drug-resistant. Dr. Katyal and the team focus on adherence support, side-effect management and follow-up testing to make sure treatment succeeds.
Drug-resistant TB needs longer, individualised regimens guided by drug-susceptibility testing, with careful monitoring for side-effects. These cases are managed in close coordination with the government programme, and may involve additional private specialist input for complex monitoring and supportive care. Note that while standard DOTS treatment is free, the pathway for MDR-TB is more involved and is planned individually β we will explain the options clearly rather than quote a fixed price. [CONFIRM: any private MDR-TB support services and charges at Gini]
Most tuberculosis is treated on an outpatient basis while the person continues daily life. Hospital admission is needed for severe or complicated disease:
Gini Advanced Care Hospital provides intensivist-led ICU support, including oxygen and ventilation, for these situations, under Dr. Rahul Katyal, Director of Critical Care. [CONFIRM: ICU bed count]
Dr. Katyal diagnoses and manages both pulmonary and extrapulmonary tuberculosis, including complex and drug-resistant cases. He works within the framework of the government's free DOTS programme, focusing on accurate diagnosis, adherence support and follow-up so that patients complete treatment and are cured β and provides critical-care support for the small number of patients with severe or complicated TB.
This patient-education page is part of Gini Health's commitment to clear, evidence-based information for the Mohali and Chandigarh Tri-City community. For official programme information, visit the government NIKSHAY portal.
Contributing β Gurjot Narwal, Founder
OPD: MonβSat Β· Gini Advanced Care Hospital, Sector 69, SAS Nagar (Mohali)